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Matthias Schwab1,2,3 and Ulrich M. Zanger1,2*
1 Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany, 2 University of Tuebingen, Tuebingen,
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The cytochrome P450, CYP2C8, metabolizes more than 60 clinically used drugs as
well as endogenous substances including retinoic acid and arachidonic acid. However,
predictive factors for interindividual variability in the efficacy and toxicity of CYP2C8
drug substrates are essentially lacking. Recently we demonstrated that peroxisome
proliferator-activated receptor alpha (PPARα), a nuclear receptor primarily involved in
control of lipid and energy homeostasis directly regulates the transcription of CYP3A4.
Here we investigated the potential regulation of CYP2C8 by PPARα. Two linked intronic
SNPs in PPARα (rs4253728, rs4823613) previously associated with hepatic CYP3A4
status showed significant association with CYP2C8 protein level in human liver samples
(N = 150). Furthermore, siRNA-mediated knock-down of PPARα in HepaRG human
hepatocyte cells resulted in up to ∼60 and ∼50% downregulation of CYP2C8 mRNA
and activity, while treatment with the PPARα agonist WY14,643 lead to an induction by
>150 and >100%, respectively. Using chromatin immunoprecipitation scanning assay
we identified a specific upstream gene region that is occupied in vivo by PPARα.
Electromobility shift assay demonstrated direct binding of PPARα to a DR-1 motif
located at positions –2762/–2775 bp upstream of the CYP2C8 transcription start site.
We further validated the functional activity of this element using luciferase reporter
gene assays in HuH7 cells. Moreover, based on our previous studies we demonstrated
that WNT/β-catenin acts as a functional inhibitor of PPARα-mediated inducibility of
CYP2C8 expression. In conclusion, our data suggest direct involvement of PPARα in
both constitutive and inducible regulation of CYP2C8 expression in human liver, which is
further modulated by WNT/β-catenin pathway. PPARA gene polymorphism could have
a modest influence on CYP2C8 phenotype.
Keywords: chromatin immunoprecipitation, diet–drug interaction, drug metabolism, genotype–phenotype
correlation, HepaRG cells, nuclear receptors, transcriptional regulation, WNT/β-catenin
Abbreviations: CAR, constitutive androstane receptor; ChIP, chromatin immunoprecipitation; CYP, cytochrome P450;
DMSO, dimethyl sulfoxide; DR, direct repeat; EMSA, electrophoretic mobility shift assays; GGT, serum gamma glutamyl
transferase; HMGCR, 3-hydroxy-3-methyl-glutaryl-CoA reductase; HNF, hepatocyte nuclear factor; PBR, PPARa-binding
region; P450, cytochrome P450; PPARα, peroxisome proliferator-activated receptor alpha; PPRE, peroxisome proliferator
response element; PXR, pregnane X receptor; RXR, retinoid X receptor; siRNA, small interfering RNA; WY14,643,
4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio acetic acid.
Frontiers in Pharmacology | www.frontiersin.org 1 November 2015 | Volume 6 | Article 261
Thomas et al. Direct PPARα-mediated regulation of CYP2C8
INTRODUCTION
The humanCYP2C subfamily consists of four highly homologous
genes, CYP2C18, CYP2C19, CYP2C9, and CYP2C8, which
are localized in this order in a ∼390 kb gene cluster on
chromosome 10q23.3. The CYP2C8 is responsible for the
oxidative metabolism of many clinically available drugs from
a diverse number of drug classes, including thiazolidinedione
and meglitinide antidiabetics, non-steroidal anti-inﬂammatory
agents (NSAIDs), antimalarials (e.g., amodiaquine, chloroquine),
chemotherapeutics (e.g., taxanes, imatinib), and numerous other
drugs (Daily and Aquilante, 2009; Xiaoping et al., 2013;
Zanger and Schwab, 2013). CYP2C8 is also involved in the
endogenous metabolism of arachidonic acid and all-trans-
retinoic acid to epoxyeicosatrienoic acids and 4-hydroxy-all-
trans-retinoic acid, respectively (Zeldin et al., 1996; McSorley
and Daly, 2000). CYP2C8 shares more common substrates
with CYP3A4 than it does with CYP2C9, despite its closer
sequence homology to CYP2C9 (Totah and Rettie, 2005). All
CYP2C enzymes are primarily expressed in liver although
lower levels of functional CYP2C enzymes are also expressed
in extrahepatic tissues, e.g., in human small intestine and in
cardiovascular tissues (DeLozier et al., 2007; Achour et al.,
2014). While CYP2C9 is the major CYP2C subfamily isoform
in human liver, CYP2C8 has been suggested to be the major
fetal CYP2C form (Achour et al., 2014; Johansson et al., 2014).
Interestingly, hepatic expression of CYP2C8 is rather strongly
correlated to CYP3A4 (Naraharisetti et al., 2010; Achour et al.,
2014).
Although the CYP2C subfamily members CYP2C9 and
CYP2C19 show clinically relevant genetic polymorphism,
there is conﬂicting data regarding polymorphic eﬀects on
CYP2C8. While it has been reported that clearance of
CYP2C8 substrates repaglinide, rosiglitazone, and pioglitazone
is increased in homozygous and heterozygous carriers of
CYP2C8∗3 (Niemi et al., 2005; Kirchheiner et al., 2006; Tornio
et al., 2008), other in vitro and in vivo showed contradictory
results (Bahadur et al., 2002; Dai et al., 2001; Daily and
Aquilante, 2009). Moreover, the CYP2C8∗4 allele did not
inﬂuence the pharmacokinetics of repaglinide (Niemi et al.,
2003).
Thus, compared to other CYP2C genes, CYP2C8 appears to be
less strongly aﬀected by genetic variation and consequently
regulatory events may have a more signiﬁcant impact on
variability. The transcriptional regulation of CYP2C genes has
been thoroughly studied implying constitutive regulation by
involving the liver-enriched receptor HNF4 (Jover et al., 2001;
Ferguson et al., 2005; Rana et al., 2010; Yue et al., 2010) as
well as inducible regulation with xenobiotic-sensing receptors
CAR, PXR, and glucocorticoid receptor (GR) playing major roles
(Pascussi et al., 2000; Ferguson et al., 2005; Chen and Goldstein,
2009; Rana et al., 2010). Interestingly, Prueksaritanont et al.
(2005) observed pronounced induction of CYP3A4 and CYP2C8
in human hepatocytes by a series of ﬁbrates including cloﬁbric
and fenoﬁbric acids and gemﬁbrozil, but failed to link this to
the ﬁbrate receptor, PPARα. The ﬁnding was conﬁrmed by other
studies and appeared to be human-speciﬁc (Richert et al., 2008;
Rakhshandehroo et al., 2009). While PPARα had been shown
to transcriptionally activate some Phase II conjugating enzymes
(e.g., EPHX2, GSTA, and UGT1A9; Barbier et al., 2009), direct
regulation of cytochrome P450s was only recently shown by
our group (Klein et al., 2012; Thomas et al., 2013). Elucidation
of the molecular mechanism of PPARα-mediated regulation of
CYP3A4 revealed direct transcriptional activation of the CYP3A4
promoter via at least three functional PPARα-binding regions
(PBR-I, -II, and -III) within ∼12 kb of the CYP3A4 upstream
gene region (Thomas et al., 2013). More recently, we found that
the PPARα-mediated eﬀects on CYP expression were additionally
modulated by the WNT/β-catenin pathway (Thomas et al.,
2015b).
In this context of CYP2C8 pharmacogenetics and
expression regulation, the aims of this study were: (a) to
characterize hepatic CYP2C8 expression variability in 150
liver samples from white individuals; (b) to assess the
impact of two PPARA polymorphisms, previously shown to
correlate with CYP3A4, on the expression and activity of
CYP2C8; (c) to investigate the potential direct regulation
of CYP2C8 by PPARα in human hepatocytes; and (d) to
further elucidate the molecular basis for the modulation of
PPARα-mediated eﬀects on CYP2C8 by the WNT/β-catenin
pathway. We demonstrate that PPARα directly binds and
regulates CYP2C8 via speciﬁc binding elements within the
CYP2C8 promoter. We also ﬁnd a moderate inﬂuence of
PPARA gene polymorphisms on hepatic CYP2C8 phenotype.
These novel ﬁndings may help to better understand the
interindividual variability in the response to various CYP2C8
drug substrates.
MATERIALS AND METHODS
Cell Culture and Treatments
Detailed description of culturing HepaRG cells can be found
elsewhere (Klein et al., 2015). Brieﬂy, HepaRG cells (batch
HPR101007) were obtained from Biopredic International
(Rennes, France) and expanded according to the provider’s
instructions. The cells were cultivated for the ﬁrst 14 days
in HepaRG growth medium based on William’s E Medium
with supplements. At the ﬁnal stage, HepaRG cells reached a
diﬀerentiated hepatocyte-like morphology and showed liver-
speciﬁc functions. The cells were further maintained in HepaRG
diﬀerentiation medium for the duration of the experiments with
exchange of medium every 2 days. All cells were maintained at
37◦C and 5% CO2 in a humidiﬁed atmosphere throughout the
experiment.
Transfections with siRNAs
For the RNA interference experiments, HepaRG cells were
transfected with 20 nM siRNAs using 10 pmol Lipofectamine
RNAiMAX Transfection Reagent (Life Technologies) in 12-
well plates with serum-free medium. The siRNA targeting
PPARα (Thomas et al., 2014, 2015a), β-catenin (Thomas et al.,
2015b), and a non-targeting siRNA as a negative control (Lo
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GC Duplex 2) were obtained from Life Technologies. One-
hundred microliters of the transfection cocktail was added per
well to the cells containing 100 μl culture medium. Upon
20 min of complex formation, the liposomes were given to
the cells. Twenty-four hours after the transfection cells were
treated for an additional 48 h with 100 μM of PPARa agonist,
WY14,643 (Sigma–Aldrich) or solvent control, DMSO (Sigma–
Aldrich).
Human Liver Cohort
Liver tissues and corresponding blood samples were previously
collected from 150 patients of Caucasian ethnicity (71 males and
79 females; average age of the subjects 58 ± 14 years). Patients
who suﬀered from hepatitis, cirrhosis, or alcohol abuse were
excluded. All tissue samples had been examined by a pathologist
and only histologically non-tumorous tissue was used (Schröder
et al., 2013). The study was approved by the ethics committees
of the medical faculties of the Charité, Humboldt University,
and of the University of Tuebingen and conducted in accordance
with the Declaration of Helsinki. Written informed consent was
obtained from each patient.
Quantitative Real-time RT-PCR Gene
Expression Analysis
For the determination of the absolute amounts of CYP2C8
mRNA expresion in the cohort of the liver samples, high quality
total RNA was isolated from liver tissue using Trizol/Qiagen
RNeasy protocol as described previously (Gomes et al., 2009).
Synthesis of cDNA was performed with 1 μg RNA using the
TaqMan Reverse Transcription Kit (Applied Biosystems)
according to the supplier’s instructions. Expression of CYP2C8
mRNA in liver tissue was performed using a commercially
purchased gene expression assay (Applied Biosystems,
Hs_00946140_g1) with a TaqMan 7500 system (Applied
Biosystems). A standard curve was obtained using CYP2C8
cDNA-containing linearized plasmid DNA purchased from
OriGene (SC107944). Raw data were normalized to RPLP0 (60S
large ribosomal protein P0) expression which was shown to
be the most suitable reference gene in the liver tissue cohort
using geNorm analysis (Vandesompele et al., 2002). RPLP0 was
determined in the same samples using the endogenous control
assay (4326314E) from Applied Biosystems. Normalized values
were adjusted to the median value of all samples.
For qRT-PCR analysis of treated HepaRG cells, total RNA
was isolated from HepaRG cells using the RNeasy Mini Kit,
including on-column genomic DNA digestion with RNase free
DNase Set (Qiagen). RNA was reverse transcribed to cDNA
with TaqMan Reverse Transcription Reagents (Applera GmbH).
Quantiﬁcation of CYP2C8 expression was performed using ABI
Applied Biosystems
R© 7500 Real-Time PCR System following
the manufacturer’s instructions using Life Technologies Assays
(Hs_00946140_g1 for CYP2C8 and 4326314E for housekeeping
gene, RPLP0). The mRNA expression levels were normalized to
the RPLP0 mRNA expression. Relative gene expression changes
were calculated using the delta delta Ct (Ct)-method (Livak
and Schmittgen, 2001; Feuer et al., 2015).
Western Blot Detection of Protein
Expression
CYP2C8 protein expression in the liver microsomes of the
liver samples cohort or following HepaRG cell treatments was
analyzed by Western blot. Ten micrograms of protein were
separated by electrophoresis on a 10% SDS-polyacrylamide gel
and blotted to nitrocellulose membranes. Anti-human CYP2C8
monoclonal antibody (Rabbit anti-human CYP2C8, Puracyp #
Hu-A004) and IRD800-labeled secondary anti-rabbit antibody
(Li-cor) were used for detection with an Odyssey system (Li-cor).
For absolute quantiﬁcation, a standard curve was generated by
coanalyzing 250–4000 fmol of recombinantly expressed CYP2C8
(Becton Dickinson Gentest 455112) in each experiment.
Transfections and Luciferase Reporter
Analyses
Cells were transfected with the Fireﬂy luciferase reporter
constructs using standard methods as recently described
(Thomas et al., 2013, 2015a). The plasmid pRL-CMV, encoding
Renilla luciferase under the control of a constitutively active viral
promoter, was co-transfected for normalization purposes. 24 h
after seeding of the cells, 800 ng of plasmid DNA (750 ng of the
respective Fireﬂy luciferase reporter plasmid, 50 ng pRL-CMV)
were transfected per well of a 24-well plate using Lipofectamine
2000 (Invitrogen). Fireﬂy luciferase reporter plasmids used in the
study were: a pGL3-based 4xPPRE-driven reporter for luciferase
expression under the control of 4 rat PPRE sites responsive to
activation by the PPARα (“pGL3-PPRE pos”; Thomas et al., 2013)
and a pGL3-based reporter plasmids driven by approximately
1000 bp of the human CYP2C8 promoter region between –
2500/–3500 bp (“pGL3-CYP2C8-Site C”) and –8500/–9500 bp
(“pGL3-CYP2C8-Site A”) to test the functional activation of the
predicted sites. For the conﬁrmations of the functional activity
of the binding motifs following mutations were introduced
(shown in bold): TCCCATTTGATGCTTC [“pGL3-CYP2C8-
Site A∗(mut)”]; ATCTCGAAGTCTAC [“pGL3-CYP2C8-Site
C∗ (mut)”]. The plasmids were generated by GenScript
sequence Synthesis Company. Transfection experiments with
the pGL3Basic empty vector were conducted as controls. Cells
were incubated with 100 μM WY14,643 or v/v DMSO control
for 48 h prior to lysis with 1x Passive Lysis Buﬀer (Promega)
and luciferase activity determination as previously described
(Thomas et al., 2013).
Assessment of CYP Metabolic Activities
Cytochrome P450 enzyme activities were determined in the
cohort of human liver samples and HepaRG cell culture
supernatants using a liquid chromatography with tandem
mass spectrometry-based substrate cocktail assay, as previously
described (Feidt et al., 2010). The CYP substrate mix was
added to cell cultures after 45 h of incubation with the
enzyme inducers as detailed above. The following substrates
were used: 50 μM phenacetin (CYP1A2), 25 μM bupropion
(CYP2B6), 5 μM amodiaquin (CYP2C8), 100 μM tolbutamide
(CYP2C9), 5 μM propafenone (CYP2D6), 100 μM atorvastatin
(CYP3A4). Aliquots of the supernatant were taken after 3 h
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TABLE 1 | Population variability of hepatic CYP2C8 expression phenotypes
(n = 150).
CYP2C8
mRNA
CYP2C8
Protein
CYP2C8
Activity
Minimum 0.08 7.52 204.2
Median 0.54 88.42 1212.6
Maximum 2.38 492.23 3212.2
Normal distribution No No No
Ratio
maximum/minimum
29.8 65.5 15.7
Coefficient of variation
(-%)
65.46 74.11 43.19
of incubation at 37◦C. Metabolite formation was normalized to
cellular protein content.
Fluorescence-based Electromobility
Shift Assays
Human PPARα and RXRα proteins were synthesized
using expression plasmids and TNT T7 Quick Coupled
Transcription/Translation System (Promega). EMSA probes
consisted of IRD700-ﬂuorescence-labeled double-stranded
oligonucleotides prepared by hybridization of complementary
single-stranded 5′IRD700 labeled oligonucleotides (Metabion)
by annealing at 100◦C for 3 min and gradually cooling down at
0.1◦C/sec to 20◦C. The reaction mixtures (20 μl) containing 3 μl
of TNT-Protein, 50 fmol of ﬂuorescence-labeled probe, 1 μg of
poly(dI-dT), 10 mM Tris-HCl, (pH 7.5), 50 mM KCl, 10 mM
MgCl2, 3.5 mMDTT, 0.25% Tween 20 were incubated for 30 min
at room temperature. The reaction mixtures were then loaded on
a native pre-electrophoresed 5% acrylamide gel (acrylamide/bis
30:1) and run at 100 V for 1.5 h in TGE-Buﬀer (25 mM Tris,
0.19 M Glycine, 1.34 mM EDTA, pH 8.3). Fluorescence was
detected using Odyssey Infrared scanner (Li-cor).
The oligonucleotides used as ﬂuorescent labeled probes for
EMSA are listed in the Supplementary Table S1. Anti–PPARα
antibody (sc-9000; Santa Cruz Biotechnology) was used for the
supershift assays.
Chromatin Immunoprecipitation Assay
Chromatin immunoprecipitation was performed usingMAGnify
Chromatin Immunoprecipitation Kit (Invitrogen) according to
the manufacturer’s description and as previously described
(Thomas et al., 2013). Brieﬂy, DNA was sheared by sonication
to an average length of ∼800 bp using Bioruptor (Diagenode)
and incubated with 10 μg of anti-PPARα antibody (PP-H0723-
00; R&D Systems), previously bound to 10 μl of magnetic beads
at 4◦C for 2 h, and DNA was puriﬁed using DNA puriﬁcation
beads and eluted in 150 μl of elution buﬀer. Promoter
occupation was analyzed with 5 μl of immunoprecipitated DNA
by Sybr-Green polymerase chain reaction (PCR). The results
were normalized to HMGCR (3-hydroxy-3-methyl-glutaryl-CoA
reductase) promoter region (–21970/–22200 bp) used as positive
control (van der Meer et al., 2010) and the untranscribed region
Untr-5 as negative control (Hariparsad et al., 2009).
Statistical Analyses
Statistical analyses were performed using software R-3.2.01
with additional packages coin_1.0-24 (Hothorn et al., 2006),
quantreg_5.112, and RVAideMemoire_0.9-503. Spearman’s rank
correlation coeﬃcient was used to assess associations between
CYP2C8 phenotypes (amodiaquine N-demethylation, CYP2C8
protein and mRNA expression) and of PPARα protein and
mRNA expression. The eﬀect of each PPARA-SNP on each
of the three CYP2C8 phenotypes was studied in three genetic
models: dominant, recessive, and additivemodel. For the ﬁrst two
genetic models, Wilcoxon–Mann–Whitney tests were applied
for univariate association analyses, whereas the last model
was investigated by Spearman correlation tests. In addition,
multivariate analyses were performed considering 10 non-genetic
factors (age, gender, nicotine and alcohol intake, exposure to
P450 inducers, total bilirubin, GGT, CRP, cholestasis, diagnosis;
Klein et al., 2010). To be more precise, for each of the CYP2C8
phenotypes, each SNP, and each genetic model, two median
regression ﬁts were compared with function anova.rq of library
quantreg (using a rank test with Wilcoxon scores): (a) with the
SNP in the respective genetic model plus the ten non-genetic
factors and (b) only with the ten non-genetic factors. Reported
p-values were adjusted for multiple testing (Bonferroni) where
appropriate. For all calculations, all data were used, including all
outlier data presented in various graphics. All statistical tests were
two-sided and statistical signiﬁcance was deﬁned as p< 0.05; 95%
conﬁdence intervals (95% CI) were reported where appropriate.
RESULTS
Population Variability of Hepatic CYP2C8
We quantitated CYP2C8 hepatic phenotypes, i.e., mRNA,
protein, and enzyme activity in RNA and microsomes of
a cohort of 150 human liver samples, and examined the
eﬀect of non-genetic parameters. CYP2C8 expression varied
considerably at the diﬀerent phenotype levels and was not
normally distributed (Table 1, Figure 1). Fold-variation was
highest (65.5-fold) for protein and lowest (15.7-fold) for enzyme
activity (Table 1), while the coeﬃcient of variation (cv) as
a normalized measure of variability was more comparable
between the diﬀerent phenotypes. These values are comparable
to previous studies (Rodríguez-Antona et al., 2007; Naraharisetti
et al., 2010), however, compared to our studies on other liver
drug metabolizing enzymes [e.g., CYPs 2D6 (Zanger et al., 2001),
2B6 (Hofmann et al., 2008), and 3A4 (Wolbold et al., 2003)],
CYP2C8 variation appeared to be somewhat less pronounced.
All three CYP2C8 phenotypes were signiﬁcantly, but moderately
correlated to each other (Figure 1). We also conﬁrmed a
signiﬁcant correlation between CYP2C8 and CYP3A4 (e.g.,
rs = 0.51, P < 0.0001 for protein level; Naraharisetti et al., 2010;
Achour et al., 2014).
1www.r-project.org
2http://CRAN.R-project.org/package=quantreg
3http://CRAN.R-project.org/package=RVAideMemoire
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FIGURE 1 | Spearman correlations and population distribution of hepatic CYP2C8 phenotypes. CYP2C8 mRNA was determined by a specific TaqMan
real-time RT-PCR assay, protein was determined by Western blotting and enzyme activity was measured by LC–MSMS analysis of amodiaquine N-desethylation in
human liver microsomes (n = 150). Results are means of duplicate measurements. (A–C) Spearman’s rank correlation coefficients are indicated as rs and statistical
significance for all comparisons was p < 0.0001. (D) Histograms showing population distributions for mRNA (top), protein (middle), and enzyme activity (bottom)
using 20 bins over the entire phenotype range.
Non-genetic Factors Influencing CYP2C8
Expression
Available documentation to the liver donors included
demographic, clinical, and self-reported data as previously
reported (Klein et al., 2010). We used multivariate modeling
to analyze whether any of these parameters had an impact on
CYP2C8 phenotype. We identiﬁed cholestasis and increased
bilirubin and GGT levels as factors being signiﬁcantly associated
with at least one microsomal CYP2C8 phenotype (Table 2). Liver
donors diagnosed with cholestasis (Nies et al., 2009) had lower
CYP2C8 protein levels (median diﬀerence, –26.8 pmol/mg [95%
CI, 6.1–47.8]; donors with abnormal bilirubin serum levels had
lower levels of protein (–36.47 pmol/mg [95% CI, 17.21–58.56])
and enzyme activity (–351.8 pmol/mg/min [95% CI, 125.95–
562.92]); and donors with elevated serum gamma glutamyl
transferase also had decreased protein levels (–17.52 pmol/mg
[95% CI, 0.83–35.62]). After correction for multiple testing only
increased serum bilirubin levels remained signiﬁcantly associated
with decreased CYP2C8 protein and enzyme activity.
Hepatic Expression and Genotype of
PPARA Correlates with CYP2C8
Phenotypes
Based on our previous studies describing impact of PPARα on
the regulation of P450 enzymes, we assessed the correlation
between PPARα expression and CYP2C8 phenotypes in our
human liver cohort. As shown in Figure 2A, mRNA expression
of PPARA was moderately but signiﬁcantly correlated to mRNA
(rs = 0.42; p < 0.0001), protein (rs = 0.24; p < 0.005) and
activity (rs = 0.25; p < 0.005) of CYP2C8, while we did not
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TABLE 2 | Influence of non-genetic factors on CYP2C8 phenotype.
Non-genetic
factora
Association
testb
mRNAc Proteinc Activityc
SEX WMW 0.119 0.068 0.618
AGE Spearman 0.321 0.577 0.106
NIC WMW 0.375 0.988 0.895
ALC WMW 0.257 0.681 0.149
DIAG KW 0.363 0.198 0.231
CHOL WMW 0.053 0.013 0.087
IND WMW 0.488 0.729 0.552
BILI WMW 0.094 0.0004 0.003
GGT WMW 0.51 0.041 0.019
CRP WMW 0.622 0.083 0.403
aNIC, nicotine consumption: non-smokers vs. smokers (>1 cigarettes/day); ALC,
alcohol consumption: none vs. >1 times/week; IND, exposure to known inducers
of P450; BILI, serum total bilirubin; GGT, serum gamma glutamyl transferase; CRP,
C-reactive protein; DIAG, diagnosis; CHOL, cholestasis.
bWMW, Wilcoxon–Mann–Whitney test; Spearman, Spearman’s correlation test;
KW, Kruskal–Wallis test.
cp-values for univariate analyses using the given association test and were not
corrected for multiple testing; p-values significant after Bonferroni correction are
shown in bold type.
observe any signiﬁcant correlation between PPARα protein and
any phenotype of CYP2C8.
Additionally, we assessed the impact of two linked PPARA
variants, rs4253728 and rs4823613, previously shown to correlate
with CYP3A4 (Klein et al., 2012), on the expression and activity
of CYP2C8 by univariate analysis, applying three diﬀerent genetic
models (dominant, recessive, or additive, see Materials and
Methods). The additive model is based on the assumption of
a gene-dose eﬀect, such that heterozygotes are phenotypically
intermediate between homozygous wild-types and mutants.
Without correction for non-genetic factors, we found for both
SNPs signiﬁcantly decreased levels of CYP2C8 protein expression
in homozygous carriers of the minor allele (Figure 2B). However,
after correction for non-genetic factors and adjustment for
multiple testing these relationships did not remain signiﬁcant.
Ligand-mediated PPARα Activation and
PPARA Gene Knockdown Modulates
CYP2C8 Expression in HepaRG Cells
To directly investigate the functional impact of PPARα on
CYP2C8 we applied two available strategies, namely stimulation
with the canonical PPARα ligand, WY14,643, and depletion of
PPARα using siRNA-mediate gene knock down. As shown in
Figure 3A, treatment of HepaRG cells with 100 μM WY14,643
signiﬁcantly induced the expression of CYP2C8 at mRNA
(more than threefold), protein (Figure 3B, lane WY14,643) and
activity (over twofold) levels, conﬁrming earlier observations
by Prueksaritanont et al. (2005). In the same experimental set-
up, transfection of HepaRG cells with PPARα-targeting siRNA
resulted in >50% reduction in the expression of mRNA and
>40% decrease in protein levels (Figure 3B, lane siPPARa)
of CYP2C8 as compared with cells treated with non-silencing
siRNA. The measurement of corresponding CYP2C8 enzyme
activity after PPARA gene silencing resulted in an average
amodiaquine N-desethylation reduction over 45% as compared
with non-targeting control. These ﬁndings demonstrated that
PPARα mediates both basal and inducible regulation of CYP2C8
in human hepatocytes.
Chromatin Immunoprecipitation (ChIP)
Identifies a CYP2C8 Promoter Region
Occupied by PPARα in HepaRG Cells
In silico analysis of the CYP2C8 promoter and upstream region
(10 kb) identiﬁed a number of putative direct repeat DR1 and
DR2 motifs with diﬀerent degrees of homology to the consensus
peroxisome proliferator response element, PPRE, AGGTCA half
site, although no 100% consensus motif was found. Thus, we
systematically screened ∼10 kb of upstream region by ChIP
of isolated chromatin from HepaRG cells using a total of 12
primer pairs. As evident from Figure 4, one region designated
as PPARα-binding region (PBR-C, spanning between –2500
and –3300 bp) showed signiﬁcant enrichment of promoter
binding by PPARα compared with unoccupied intermediary gene
regions and negative control (n.c.). Interestingly, pre-treatment
of hepatocytes with 10 μM of CYP2C8 substrate, amodiaquine,
resulted in≈40%higher enrichment of PPARα occupation within
this region (Figure 4, red bars).
PPARα Directly Binds to the Specific
Motifs of CYP2C8 Promoter and
Activates its Expression.
We next investigated whether PPARα/RXRα heterodimer can
directly bind to their bioinformatically predicted potential sites
using ﬂuorescence-based EMSA. Figure 5A shows results for a
selection of six motifs with the highest score for binding to the
in silico predicted DR1/DR2 motifs out of a total of 15 tested
motifs (Supplementary Table S1). We found that PPARα/RXRα
speciﬁcally bound to two identiﬁed motifs, one of which
is the DR-4 PXR/CAR-binding site, TCAACTTTGATGACCC
positioned between (–8806/–8822), previously identiﬁed by
Ferguson et al. (2005). However, the newly identiﬁed DR1
PPRE motif, AGTTCGAAGTTCA within the identiﬁed PBR-
C positioned between –2762/–2775 bp was bound with much
higher apparent aﬃnity (Figure 5A).
Furthermore, results of HuH7 cell cotransfection experiments
performed in the absence and presence of WY14,643 are shown
in Figure 5B. Luciferase reporter gene analysis of the CYP2C8
upstream promoter region incorporating PBRs- A and C showed
over fourfold induction of PPARα activation by WY14,643.
Furthermore, mutation of sites DR4-A and DR1-C completely
abolished inducible PPARα-dependent transactivation of
CYP2C8. These data further conﬁrm functional activity of
two motifs within CYP2C8 promoter, which can be bound by
PPARα.
WNT/β-Catenin Functions as an Inhibitor
of PPARα-mediated CYP2C8 Induction
We recently reported on the crosstalk between the PPARα and
WNT/β-catenin pathways in the regulation of P450 enzymes
which results in an inhibitory inﬂuence of β-catenin on
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FIGURE 2 | Influence of PPARα expression and genotype on the CYP2C8 phenotype. (A) Scatter plots of CYP2C8 phenotypes (amodiaquine
N-desethylation, CYP2C8 protein and mRNA expression) vs. PPARα mRNA (top) and protein (bottom) expression. Spearman’s rank correlation coefficient rs and
corresponding p-values are given. (B) Box-and-whisker plots of CYP2C8 phenotypes (Amodiaquine N-desethylation, CYP2C8 protein and mRNA expression) for
two previously described intronic PPARA variants. Genotypes are indicated as G/G, G/A, and A/A (for rs4253728) and A/A, A/G, and G/G (for rs4823613). P (rec.),
unadjusted p-value of Wilcoxon–Mann–Whitney test for recessive genetic model; N, number of individuals per group; numbers for the three genotype groups do not
add up to 150 due to missing values. Outliers were included in all calculations.
PPARα-mediated induction of CYP3A4 as well as CYP2C8
mRNA (Thomas et al., 2015b). Here we simultaneously analyzed
mRNA and protein expression of CYP2C8 following PPARα
activation by WY14,643, either in the presence of β-catenin
targeting siRNA, siCatenin, or non-targeting siRNA, siCTR
(Figure 6). In line with our previous observations, knockdown of
β-catenin in the presence of WY14,643 led to increased CYP2C8
expression by activated PPARα (Figure 6A) on the mRNA (gray
bars) and protein (black bars) level (Figure 6B). Thus it can
be concluded that in HepaRG cells β-catenin exerts a similar
inhibitory modulation on PPARα-mediated CYP2C8 induction
as previously shown for CYP3A4 regulation.
DISCUSSION
In the present study, we demonstrated direct binding of the
nuclear receptor PPARα to the CYP2C8 promoter resulting in its
transcriptional activation and regulation of CYP2C8 expression
in hepatocytes and in human liver. We identiﬁed two speciﬁc
regulatory elements that are essential for PPARα-mediated
transactivation. One of them corresponds to the previously
identiﬁed CAR/PXR-binding site at –8806 bp (DR-4) that had
been shown to be essential for the activation of the CYP2C8
promoter by both the PXR ligand rifampicin and the human CAR
ligand, CITCO (Maglich et al., 2003). In addition we identiﬁed
Frontiers in Pharmacology | www.frontiersin.org 7 November 2015 | Volume 6 | Article 261
Thomas et al. Direct PPARα-mediated regulation of CYP2C8
FIGURE 3 | PPARα knockdown and activation in HepaRG cells. (A) mRNA levels were measured in HepaRG cultures cultured in three independent
differentiation batches 72 h after PPARα activation using ligand WY14,643 (left part of the diagram) or siRNA-mediated PPARα knock-down (right part of the
diagram) and compared with mRNA levels measured in cells treated with either DMSO (left) or non-targeting siRNA (right) set at 1.0. The graph shows the means
from three (mRNA, activity) or two (protein) independent experiments, with error bars indicating standard deviations (mRNA, activity) and dots representing individual
data points (protein). ∗, Statistically significant (P < 0.05, paired t-test). (B) Representative Western Blot analysis of the corresponding protein levels of CYP2C8
following either ligand-mediated induction (lanes DMSO and WY14,643) or siRNA-mediated knock-down (lanes siPPARa and siCTR) of PPARα.
FIGURE 4 | Binding of PPARα to the CYP2C8 promoter in vivo. Precipitated DNA from HepaRG cells without (w/o) treatment or after treatment with
amodiaquine (10 μM for 6 h) was purified and was used, together with input DNA, as template for Sybr-Green PCR using a total of 12 primer pairs spanning
approximately 10 kb of the CYP2C8 promoter region. Raw Ct (cycle threshold) values were normalized to input DNA to calculate the percentage of DNA
immunoprecipitated. Primers encompassing the PPRE of the human HMGCR gene were used as positive control. Means relative to negative control primer pair (n.c.)
are shown. (A–F) Schematic representation of CYP2C8 promoter regions, which were subjected for the ChIP analysis. Promoter scheme includes binding sites of
previously described transcription factors.
a novel PPRE DR-1motif at –2762/–2775 bp region, which is
independently of the former site suﬃcient for PPARα-mediated
regulation.
For the direct regulation of CYP2C8 expression by PPARα
we provide three lines of evidence: ﬁrst, ChIP in HepaRG
cells revealed a PPARα binding region between –2500 and –
3500 bp upstream of transcriptional start site in vivo; second,
two motifs for PPARα/RXRα binding (DR4-A and DR1-C)
were identiﬁed and further conﬁrmed by EMSA; and third,
reporter gene analysis demonstrated that both of these motifs
are essential and suﬃcient for transcriptional activation by
PPARα. The DR4-A motif was previously shown to be a
binding site for PXR and CAR. Although EMSA revealed a
relatively weak signal of PPARα/RXRα binding to this region,
luciferase activity assay further supported the relevance of
this site for PPARα-mediated regulation (Figure 5B). We
hypothesize that probably a multifactorial complex containing
PXR/CAR and PPARα is responsible for the transcriptional
regulation on this motif. The DR1-C site displayed the strongest
binding aﬃnity, in agreement with its strong functional role,
as demonstrated by mutational analysis. The presence of
several nearby and overlapping transcription factor binding
sites may lead to protein–protein interactions that could be
explained by the robustness of the regulatory system by several
nuclear receptors. In general, our experiments suggest both
constitutive and inducible transactivation of CYP2C8 by PPARα.
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FIGURE 5 | Direct PPARα-mediated regulation of CYP2C8.
(A) Electrophoretic mobility shift assays using in vitro translated proteins was
used for assessment the binding of fluorescence-labeled double-stranded
oligonucleotide probes corresponding to the indicated regions within CYP2C8
promoter (selection out of 15 tested probes is shown). As a positive control for
binding, the known PPARα/RXRα binding site of the rat ACOX1 gene was
used (Thomas et al., 2013). Complexes of PPARα/RXRα heterodimers with
the oligonucleotides are marked by an arrow. (B) Luciferase reporter gene
constructs containing the sequences of the CYP2C8 promoter, PBR-A
(–9500/–8500 bp) and PBR-C (–2500 to –3500 bp) were cotransfected with a
PPARα expression plasmid and renilla-luciferase expression vector into HuH7
cells. Cells were treated with either 100 μM WY14,643 or vehicle DMSO for
48 h before measurement of firefly/renilla luciferase activities. Firefly luciferase
activities were normalized to renilla luciferase activities to consider changes in
the transfection variability and to DMSO control, set as 1. Data are means of
three independent experiments, each performed in triplicates in 96-well
format; (mut), mutated sites; ∗, statistically significant (P < 0.05) compared
with DMSO treatment set to 1.
Interestingly, pretreatment of hepatocytes with the CYP2C8
canonical substrate, amodiaquine, further increased enrichment
of PPARα within PBR-C as assessed by ChIP assay. Although
the exact molecular mechanisms of this increased occupation are
currently unclear, it should be noted thatWY14,643 did not show
such an eﬀect on the CYP3A4 promoter occupancy (Thomas
et al., 2013).
For the characterization of genetic and non-genetic factors
inﬂuencing interindividual variability of hepatic CYP2C8
expression we used our well characterized human liver cohort
including 150 white individuals with comprehensive clinical
documentation. We observed that environmental and other non-
genetic factors have a moderate inﬂuence on hepatic CYP2C8
phenotype. Association of CYP2C8 with deregulated bile acid
homeostasis and drug induced cholestasis have been reported
before (Daly et al., 2007; Rieger et al., 2013). In particular for
diclofenac-induced cholestasis, it was suggested that allelic
FIGURE 6 | Inhibitory role of β-catenin in the ligand-mediated induction
of CYP2C8 by PPARα. (A) mRNA (gray bars) and protein (black bars)
expression levels of CYP2C8 were analyzed by quantitative real-time qRT-PCR
and Western blotting, respectively, following treatment of HepaRG cells with
100 μM of WY14,643 in the presence of β-catenin-targeting siRNA (siCatenin)
or non-targeting control (siCTR). Shown are mean values of three independent
experiments ±SD. ∗, Statistically significant (P < 0.05) compared with DMSO
treatment set to 1; #, statistically significant (P < 0.05) when siCatenin-treated
cells compared to control siCTR-treated cells. (B) Representative western
blot analysis of CYP2C8 protein expression following WY14,643-mediated
activation of PPARα in the absence (lane siCatenin + WY14,643) or presence
(lane siCTR + WY14,643) of β-catenin.
variants in UGT2B7, CYP2C8, and MRP2 may cause an increase
in the level of reactive metabolites leading to protein-diclofenac
adducts that then produce toxicity. The observation that the two
linked PPARA variants, rs4253728, and rs4823613, previously
shown to inﬂuence CYP3A4 expression and function (Klein
et al., 2012), also aﬀect expression and activity of CYP2C8 is well
explained by the direct transcriptional regulation of CYP2C8
by PPARα and further conﬁrms the major ﬁnding of this study.
However, whether the inﬂuence of these polymorphisms is
suﬃcient to improve CYP2C8 pharmacogenetic prediction
remains to be studied.
In addition to the signiﬁcance for drug–drug interactions,
our ﬁndings may have further clinical relevance for the
treatment of lipid disorders and plasma dyslipidemia with
PPARα ligands. As a variety of dietary and endogenous lipids,
including saturated and unsaturated fatty acids, phospholipids,
eicosanoids, and many derivatives and metabolites, have been
implicated in PPARα activation, our ﬁndings suggest an intricate
interplay between intermediary metabolism, nutritional status,
and biotransformation. Of note, in our previous study we found
induction of several P450s including CYP2C8 by the common
Frontiers in Pharmacology | www.frontiersin.org 9 November 2015 | Volume 6 | Article 261
Thomas et al. Direct PPARα-mediated regulation of CYP2C8
nutritional phospholipid, POPC (Thomas et al., 2013). The
current data on direct P450 induction through PPARα suggests
a link between endogenous substances and the regulation of drug
biotransformation in human liver and stresses a clear need to
readdress the potential for drug–drug interactions, which may
depend on nutritional status. This is of particular importance
for newly developed PPARα ligands to target obesity, insulin
resistance, and diabetes (Lalloyer and Staels, 2010).
CONCLUSION
We have elucidated the mechanistic basis for constitutive and
inducible transcriptional regulation of CYP2C8 by PPARα.
PPARα thus contributes to a transcriptional network so far
including CAR, PXR, GR, and HNF4 as direct regulators
of CYP2C8 expression, while inducibility is also modulated
via WNT/β-catenin pathway. Through these studies, we
have identiﬁed two speciﬁc elements that are essential for
transcriptional activation by PPARα, and unraveling this cellular
signaling pathway will help to better understand the physiological
role of the CYP2Cs and the factors that control their inducibility
and contribute to the variability observed in humans.
AUTHOR CONTRIBUTIONS
MT, SW, BK, MT (Oulu), and KK structured and conducted the
experiments and analyzed the data. MT,MS, and UZ designed the
study and wrote the manuscript.
ACKNOWLEDGMENTS
Igor Liebermann, Christine Bayha, and Kyoko Momoi are
greatly acknowledged for excellent technical support. We thank
Christophe Chesne and Biopredic for help and support with
HepaRG cells. This study was supported by the German Federal
Ministry of Education and Research (Virtual Liver Network
Grant 0315755) and by the Robert Bosch Foundation, Stuttgart,
Germany.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fphar.
2015.00261
REFERENCES
Achour, B., Barber, J., and Rostami-Hodjegan, A. (2014). Expression
of hepatic drug-metabolizing cytochrome p450 enzymes and their
intercorrelations: a meta-analysis. Drug Metab. Dispos. 42, 1349–1356.
doi: 10.1124/dmd.114.058834
Bahadur, N., Leathart, J. B. S., Mutch, E., Steimel-Crespi, D., Dunn, S. A.,
Gilissen, R., et al. (2002). CYP2C8 polymorphisms in Caucasians and
their relationship with paclitaxel 6alpha-hydroxylase activity in human
liver microsomes. Biochem. Pharmacol. 64, 1579–1589. doi: 10.1016/S0006-
2952(02)01354-0
Barbier, O., Trottier, J., Kaeding, J., Caron, P., and Verreault, M. (2009). Lipid-
activated transcription factors control bile acid glucuronidation. Mol. Cell
Biochem. 326, 3–8. doi: 10.1007/s11010-008-0001-5
Chen, Y., and Goldstein, J. A. (2009). The transcriptional regulation of the human
CYP2C genes. Curr. Drug Metab. 10, 567. doi: 10.2174/138920009789375397
Dai, D., Zeldin, D. C., Blaisdell, J. A., Chanas, B., Coulter, S. J., Ghanayem, B. I.,
et al. (2001). Polymorphisms in human CYP2C8 decrease metabolism of the
anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11, 597–607.
doi: 10.1097/00008571-200110000-00006
Daily, E. B., and Aquilante, C. L. (2009). Cytochrome P450 2C8 pharmacogenetics:
a review of clinical studies. Pharmacogenomics 10, 1489–1510. doi:
10.2217/pgs.09.82
Daly, A. K., Aithal, G. P., Leathart, J. B. S., Swainsbury, R. A., Dang, T. S., and
Day, C. P. (2007). Genetic susceptibility to diclofenac-induced hepatotoxicity:
contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology
132, 272–281. doi: 10.1053/j.gastro.2006.11.023
DeLozier, T. C., Kissling, G. E., Coulter, S. J., Dai, D., Foley, J. F.,
Bradbury, J. A., et al. (2007). Detection of Human CYP2C8, CYP2C9, and
CYP2J2 in Cardiovascular Tissues. Drug Metab. Dispos. 35, 682–688. doi:
10.1124/dmd.106.012823
Feidt, D. M., Klein, K., Hofmann, U., Riedmaier, S., Knobeloch, D., Thasler,
W. E., et al. (2010). Proﬁling induction of cytochrome p450 enzyme activity
by statins using a new liquid chromatography-tandem mass spectrometry
cocktail assay in human hepatocytes. Drug Metab. Dispos. 38, 1589–1597. doi:
10.1124/dmd.110.033886
Ferguson, S. S., Chen, Y., LeCluyse, E. L., Negishi, M., and Goldstein, J. A.
(2005). Human CYP2C8 is transcriptionally regulated by the nuclear receptors
constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor,
and hepatic nuclear factor 4alpha. Mol. Pharmacol. 68, 747–757. doi:
10.1124/mol.105.013169
Feuer, R., Vlaic, S., Arlt, J., Sawodny, O., Dahmen, U., Zanger, U. M.,
et al. (2015). LEMming: a linear error model to normalize parallel
quantitative real-time PCR (qPCR) data as an alternative to reference
gene based methods. PLoS ONE 10:e0135852. doi: 10.1371/journal.pone.0
135852
Gomes, A. M., Winter, S., Klein, K., Turpeinen, M., Schaeﬀeler, E., Schwab, M.,
et al. (2009). Pharmacogenomics of human liver cytochrome P450
oxidoreductase: multifactorial analysis and impact on microsomal drug
oxidation. Pharmacogenomics 10, 579–599. doi: 10.2217/pgs.09.7
Hariparsad, N., Chu, X., Yabut, J., Labhart, P., Hartley, D. P., Dai, X., et al.
(2009). Identiﬁcation of pregnane-X receptor target genes and coactivator and
corepressor binding to promoter elements in human hepatocytes.Nucleic Acids
Res. 37, 1160–1173. doi: 10.1093/nar/gkn1047
Hofmann, M. H., Blievernicht, J. K., Klein, K., Saussele, T., Schaeﬀeler, E.,
Schwab, M., et al. (2008). Aberrant splicing caused by single nucleotide
polymorphism c.516G> T [Q172H], a marker of CYP2B6*6, is responsible for
decreased expression and activity of CYP2B6 in liver. J. Pharmacol. Exp. Ther.
325, 284–292. doi: 10.1124/jpet.107.133306
Hothorn, T., Hornik, K., van de Wiel, M. A., and Zeileis, A. (2006).
A lego system for conditional inference. Am. Stat. 60, 257–263. doi:
10.1198/000313006X118430
Johansson, M., Strahm, E., Rane, A., and Ekström, L. (2014). CYP2C8 and
CYP2C9 mRNA expression proﬁle in the human fetus. Front. Genet. 5:58. doi:
10.3389/fgene.2014.00058
Jover, R., Bort, R., Gómez-Lechón, M. J., and Castell, J. V. (2001). Cytochrome
P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study
using adenovirus-mediated antisense targeting. Hepatology 33, 668–675. doi:
10.1053/jhep.2001.22176
Kirchheiner, J., Thomas, S., Bauer, S., Tomalik-Scharte, D., Hering, U.,
Doroshyenko, O., et al. (2006). Pharmacokinetics and pharmacodynamics of
rosiglitazone in relation to CYP2C8 genotype. Clin. Pharmacol. Ther. 80,
657–667. doi: 10.1016/j.clpt.2006.09.008
Klein, K., Thomas, M., Winter, S., Nussler, A. K., Niemi, M., Schwab, M., et al.
(2012). PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo.
Clin. Pharmacol. Ther. 91, 1044–1052. doi: 10.1038/clpt.2011.336
Frontiers in Pharmacology | www.frontiersin.org 10 November 2015 | Volume 6 | Article 261
Thomas et al. Direct PPARα-mediated regulation of CYP2C8
Klein, K., Winter, S., Turpeinen, M., Schwab, M., and Zanger, U. M. (2010).
Pathway-targeted pharmacogenomics of CYP1A2 in human liver. Front.
Pharmacol. 1:129. doi: 10.3389/fphar.2010.00129
Klein, M., Thomas, M., Hofmann, U., Seehofer, D., Damm, G., and Zanger, U. M.
(2015). A systematic comparison of the impact of inﬂammatory signaling
on absorption, distribution, metabolism, and excretion gene expression and
activity in primary human hepatocytes and HepaRG cells. Drug Metab. Dispos.
43, 273–283. doi: 10.1124/dmd.114.060962
Lalloyer, F., and Staels, B. (2010). Fibrates, glitazones, and peroxisome proliferator-
activated receptors. Arterioscler. Thromb. Vasc. Biol. 30, 894–899. doi:
10.1161/ATVBAHA.108.179689
Livak, K. J., and Schmittgen, T. D. (2001). Analysis of relative gene expression
data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
Methods 25, 402–408. doi: 10.1006/meth.2001.1262
Maglich, J. M., Parks, D. J., Moore, L. B., Collins, J. L., Goodwin, B., Billin, A. N.,
et al. (2003). Identiﬁcation of a novel human constitutive androstane receptor
(CAR) agonist and its use in the identiﬁcation of CAR target genes. J. Biol.
Chem. 278, 17277–17283. doi: 10.1074/jbc.M300138200
McSorley, L. C., and Daly, A. K. (2000). Identiﬁcation of human cytochrome P450
isoforms that contribute to all-trans-retinoic acid 4-hydroxylation. Biochem.
Pharmacol. 60, 517–526. doi: 10.1016/S0006-2952(00)00356-7
Naraharisetti, S. B., Lin, Y. S., Rieder, M. J., Marciante, K. D., Psaty, B. M.,
Thummel, K. E., et al. (2010). Human liver expression of CYP2C8:
gender, age, and genotype eﬀects. Drug Metab. Dispos. 38, 889–893. doi:
10.1124/dmd.109.031542
Niemi, M., Backman, J. T., Juntti-Patinen, L., Neuvonen, M., and Neuvonen,
P. J. (2005). Coadministration of gemﬁbrozil and itraconazole has only
a minor eﬀect on the pharmacokinetics of the CYP2C9 and CYP3A4
substrate nateglinide. Br. J. Clin. Pharmacol. 60, 208–217. doi: 10.1111/j.1365-
2125.2005.02385.x
Niemi, M., Leathart, J. B., Neuvonen, M., Backman, J. T., Daly, A. K., and
Neuvonen, P. J. (2003). Polymorphism in CYP2C8 is associated with reduced
plasma concentrations of repaglinide. Clin. Pharmacol. Ther. 74, 380–387. doi:
10.1016/S0009-9236(03)00228-5
Nies, A. T., Koepsell, H., Winter, S., Burk, O., Klein, K., Kerb, R., et al.
(2009). Expression of organic cation transporters OCT1 (SLC22A1) and OCT3
(SLC22A3) is aﬀected by genetic factors and cholestasis in human liver.
Hepatology 50, 1227–1240. doi: 10.1002/hep.23103
Pascussi, J. M., Gerbal-Chaloin, S., Fabre, J. M., Maurel, P., and Vilarem, M. J.
(2000). Dexamethasone enhances constitutive androstane receptor expression
in human hepatocytes: consequences on cytochrome P450 gene regulation.Mol.
Pharmacol. 58, 1441–1450.
Prueksaritanont, T., Richards, K. M., Qiu, Y., Strong-Basalyga, K., Miller, A., Li, C.,
et al. (2005). Comparative eﬀects of ﬁbrates on drug metabolizing enzymes
in human hepatocytes. Pharm. Res. 22, 71–78. doi: 10.1007/s11095-004-
9011-5
Rakhshandehroo, M., Hooiveld, G., Müller, M., and Kersten, S. (2009).
Comparative analysis of gene regulation by the transcription factor
PPARα between mouse and human. PLoS ONE 4:e6796. doi:
10.1371/journal.pone.0006796
Rana, R., Chen, Y., Ferguson, S. S., Kissling, G. E., Surapureddi, S., and Goldstein,
J. A. (2010). Hepatocyte nuclear factor 4α regulates rifampicin-mediated
induction of CYP2C genes in primary cultures of human hepatocytes. Drug
Metab. Dispos. 38, 591–599. doi: 10.1124/dmd.109.030387
Richert, L., Tuschl, G., Viollon-Abadie, C., Blanchard, N., Bonet, A., Heyd, B.,
et al. (2008). Species diﬀerences in the response of liver drug-metabolizing
enzymes to (S)-4-O-tolylsulfanyl-2-(4-triﬂuormethyl-phenoxy)-butyric acid
(EMD 392949) in vivo and in vitro. Drug Metab. Dispos. 36, 702–714. doi:
10.1124/dmd.107.018358
Rieger, J. K., Klein, K., Winter, S., and Zanger, U. M. (2013). Expression variability
of absorption, distribution, metabolism, excretion-related microRNAs in
human liver: inﬂuence of nongenetic factors and association with gene
expression. Drug Metab. Dispos. 41, 1752–1762. doi: 10.1124/dmd.113.0
52126
Rodríguez-Antona, C., Niemi, M., Backman, J. T., Kajosaari, L. I., Neuvonen,
P. J., Robledo, M., et al. (2007). Characterization of novel CYP2C8
haplotypes and their contribution to paclitaxel and repaglinide metabolism.
Pharmacogenomics J. 8, 268–277. doi: 10.1038/sj.tpj.6500482
Schröder, A., Klein, K., Winter, S., Schwab, M., Bonin, M., Zell, A., et al. (2013).
Genomics of ADME gene expression: mapping expression quantitative trait
loci relevant for absorption, distribution, metabolism and excretion of drugs
in human liver. Pharmacogenomics J. 13, 12–20. doi: 10.1038/tpj.2011.44
Thomas, M., Bayha, C., Klein, K., Müller, S., Weiss, T. S., Schwab, M., et al. (2015a).
The truncated splice variant of peroxisome proliferator-activated receptor
alpha, PPARα-tr, autonomously regulates proliferative and pro-inﬂammatory
genes. BMC Cancer 15:488. doi: 10.1186/s12885-015-1500-x
Thomas, M., Bayha, C., Vetter, S., Hofmann, U., Schwarz, M., Zanger, U. M.,
et al. (2015b). Activating and inhibitory functions of WNT/β-catenin in the
induction of cytochromes P450 by nuclear receptors in heparg cells. Mol.
Pharmacol. 87, 1013–1020. doi: 10.1124/mol.114.097402
Thomas, M., Burk, O., Klumpp, B., Kandel, B. A., Damm, G., Weiss, T. S., et al.
(2013). Direct transcriptional regulation of human hepatic cytochrome P450
3A4 (CYP3A4) by peroxisome proliferator-activated receptor alpha (PPARα).
Mol. Pharmacol. 83, 709–718. doi: 10.1124/mol.112.082503
Thomas, M., Rieger, J. K., Kandel, B. A., Klein, K., and Zanger, U. M.
(2014). Targeting nuclear receptors with lentivirus-delivered small RNAs
in primary human hepatocytes. Cell. Physiol. Biochem. 33, 2003–2013. doi:
10.1159/000362976
Tornio, A., Niemi, M., Neuvonen, P. J., and Backman, J. T. (2008). Trimethoprim
and the CYP2C8*3 allele have opposite eﬀects on the pharmacokinetics
of pioglitazone. Drug Metab. Dispos. 36, 73–80. doi: 10.1124/dmd.107.0
18010
Totah, R. A., and Rettie, A. E. (2005). Cytochrome P450 2C8: substrates, inhibitors,
pharmacogenetics, and clinical relevance. Clin. Pharmacol. Ther. 77, 341–352.
doi: 10.1016/j.clpt.2004.12.267
van der Meer, D. L. M., Degenhardt, T., Väisänen, S., de Groot, P. J.,
Heinäniemi, M., de Vries, S. C., et al. (2010). Proﬁling of promoter occupancy
by PPARalpha in human hepatoma cells via ChIP-chip analysis. Nucleic Acids
Res. 38, 2839–2850. doi: 10.1093/nar/gkq012
Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A.,
et al. (2002). Accurate normalization of real-time quantitative RT-PCR data
by geometric averaging of multiple internal control genes. Genome Biol. 3,
.1–.0034. doi: 10.1186/gb-2002-3-7-research0034
Wolbold, R., Klein, K., Burk, O., Nüssler, A. K., Neuhaus, P., Eichelbaum, M.,
et al. (2003). Sex is a major determinant of CYP3A4 expression in human liver.
Hepatology 38, 978–988. doi: 10.1053/jhep.2003.50393
Xiaoping, L., Zhong, F., and Tan, X. (2013). Cytochrome P450 2C8
and drug metabolism. Curr. Top. Med. Chem. 13, 2241–2253. doi:
10.2174/15680266113136660157
Yue, H.-Y., Yin, C., Hou, J.-L., Zeng, X., Chen, Y.-X., Zhong, W., et al. (2010).
Hepatocyte nuclear factor 4alpha attenuates hepatic ﬁbrosis in rats. Gut 59,
236–246. doi: 10.1136/gut.2008.174904
Zanger, U. M., Fischer, J., Raimundo, S., Stüven, T., Evert, B. O., Schwab, M.,
et al. (2001). Comprehensive analysis of the genetic factors determining
expression and function of hepatic CYP2D6. Pharmacogenetics 11, 573–585.
doi: 10.1097/00008571-200110000-00004
Zanger, U. M., and Schwab, M. (2013). Cytochrome P450 enzymes in
drug metabolism: regulation of gene expression, enzyme activities,
and impact of genetic variation. Pharmacol. Ther. 138, 103–141. doi:
10.1016/j.pharmthera.2012.12.007
Zeldin,D. C.,Moomaw, C. R., Jesse,N., Tomer, K. B., Beetham, J., Hammock, B. D.,
et al. (1996). Biochemical characterization of the human liver cytochrome P450
arachidonic acid epoxygenase pathway.Arch. Biochem. Biophys. 330, 87–96. doi:
10.1006/abbi.1996.0229
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or ﬁnancial relationships that could
be construed as a potential conﬂict of interest.
Copyright © 2015 Thomas, Winter, Klumpp, Turpeinen, Klein, Schwab and Zanger.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Pharmacology | www.frontiersin.org 11 November 2015 | Volume 6 | Article 261
